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Background: Signaling networks in eukaryotes are made up of upstream and downstream subnetworks. The
upstream subnetwork contains the intertwined network of signaling pathways, while the downstream regulatory
part contains transcription factors and their binding sites on the DNA as well as microRNAs and their mRNA targets.
Currently, most signaling and regulatory databases contain only a subsection of this network, making
comprehensive analyses highly time-consuming and dependent on specific data handling expertise. The need for
detailed mapping of signaling systems is also supported by the fact that several drug development failures were
caused by undiscovered cross-talk or regulatory effects of drug targets. We previously created a uniformly curated
signaling pathway resource, SignaLink, to facilitate the analysis of pathway cross-talks. Here, we present SignaLink 2,
which significantly extends the coverage and applications of its predecessor.
Description: We developed a novel concept to integrate and utilize different subsections (i.e., layers) of the
signaling network. The multi-layered (onion-like) database structure is made up of signaling pathways, their
pathway regulators (e.g., scaffold and endocytotic proteins) and modifier enzymes (e.g., phosphatases, ubiquitin
ligases), as well as transcriptional and post-transcriptional regulators of all of these components. The user-friendly
website allows the interactive exploration of how each signaling protein is regulated. The customizable download
page enables the analysis of any user-specified part of the signaling network. Compared to other signaling
resources, distinctive features of SignaLink 2 are the following: 1) it involves experimental data not only from
humans but from two invertebrate model organisms, C. elegans and D. melanogaster; 2) combines manual curation
with large-scale datasets; 3) provides confidence scores for each interaction; 4) operates a customizable download
page with multiple file formats (e.g., BioPAX, Cytoscape, SBML). Non-profit users can access SignaLink 2 free of
charge at http://SignaLink.org.
Conclusions: With SignaLink 2 as a single resource, users can effectively analyze signaling pathways, scaffold
proteins, modifier enzymes, transcription factors and miRNAs that are important in the regulation of signaling
processes. This integrated resource allows the systems-level examination of how cross-talks and signaling flow are
regulated, as well as provide data for cross-species comparisons and drug discovery analyses.
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Reliable analyses of signaling pathways need uniform
pathway definitions and curation rules applied to all
pathways. Accordingly, we previously created Signa-
Link, a resource containing major signaling pathways
of the nematode Caenorhabditis elegans, the fruit fly
Drosophila melanogaster and humans [1]. Specific
regulation of signaling flow is essential to ensure the
appropriate response of the signaling system for a
given input [2]. Signaling flow is determined by the
spatial and temporal properties of signaling proteins
precisely regulated by cellular processes (e.g., endocyto-
sis, transcription, miRNA regulation) [3]. In addition,
signaling components are modulated by proteins hav-
ing no direct signaling functions, such as scaffold pro-
teins and ubiquitin ligases [4,5].
Despite the complexity of eukaryotic signaling net-
works, current signaling or regulation-related resources
contain only specific parts of such a global signaling net-
work. As a consequence, computational background and
expertise in different bioinformatics resources are
needed to answer questions about how a signaling path-
way is regulated, or how the pathways influence each
other through transcription and miRNA-mediated gene
silencing. A few studies already combined regulatory and
protein-protein interaction networks [6-9], while a new
resource, TranscriptomeBrowser, integrates human regu-
latory networks with phosphorylation reactions [10]. Re-
cently, we developed a systems-level resource of the
transcription factor NRF2, containing its transcriptional,
post-transcriptional and post-translational modifiers,
based on manual curation, in silico prediction and exist-
ing dataset imports [11].
Taking into consideration the need for a novel arrange-
ment of signaling and regulatory data to examine signal-
ing processes on a systems-level, we present SignaLink 2,
a database with multi-layered (onion-like) structure. Our
basic aim was to develop an integrated database that
helps anyone to understand how cellular signaling path-
ways and their cross-talks are regulated. To accomplish
this goal, SignaLink 2 contains for worms, flies and
humans 1) pathway components and cross-talks; 2) inter-
acting proteins that modify or facilitate signaling reac-
tions; and 3) regulatory components (transcription
factors and miRNAs) that affect the expression of path-
way proteins and their interactors.
Construction and content
Compilation of the multi-layered network
We developed an onion-like, multi-layered database
structure to integrate and utilize the different subsec-
tions (i.e., layers) of the signaling network. The multi-
layered structure and content of each layer is illustrated
and listed in Figure 1.The core of SignaLink 2 contains seven major pathways,
which are biochemically and evolutionary defined, and en-
compass all major developmental signaling mechanisms
[12]: RTK (receptor tyrosine kinase), TGF-ß (transforming
growth factor beta), WNT/Wingless, Hedgehog, JAK/
STAT, Notch and NHR (Nuclear hormone receptor). We
note that in the previous version of SignaLink, EGF/MAPK
(epidermal growth factor /mitogen-activated protein
kinase) and insulin/IGF (insulin growth factor) path-
ways were defined as separate pathways. In this
upgraded and extended version, the RTK pathway
contains both pathways and additional related recep-
tors (e.g., VEGFR and FGFR). This grouping is more
realistic and in line with evolutionary studies [12].
While earlier in SignaLink the NHR pathway con-
tained only the NHR proteins, it now includes their
co-factors, too. The uniform manual curation proto-
col remained the same as developed and published
earlier [1]. Accordingly, we set the pathway boundar-
ies based on expert-written reviews and manual
search of the literature. We examined the signaling
functions and interactions of the proteins mentioned
in the reviews. For each signaling interaction, we
listed the PubMed ID of the publication reporting
the verifying experiment(s). In addition, we grouped
all manually curated signaling pathway proteins to
‘core’ and ‘non-core’ proteins. A ‘core’ protein is es-
sential for transmitting the signal of its pathway,
while a ‘non-core’ protein modulates the pathway’s
core proteins but not transmit the incoming signal.
For a more detailed description on the curation
protocol, please see the supplementary material of
our earlier publication on SignaLink [1]. The current
curation update was closed in April, 2011.
We added two further extensions that can be option-
ally used. i) With manual curation, we collected scaffold
proteins and endocytosis-related proteins and linked
them to signaling pathway proteins, based on the scaf-
fold protein list of the Ref. [13] and signaling-related
endocytosis reviews, respectively. ii) We extended the
number of transcription factors (TFs) in the database
from 243 to 586 by connecting additional TFs to
already curated TFs, based on protein-protein inter-
action (PPI) data from WI8, DroID, HPRD and Bio-
GRID databases [14-17].
Next, using the ELM server [18], we searched for
enzymes (i.e., phosphatases, ubiquitin-ligases, peptidases,
etc.) that can directly modify signaling components
involved in SignaLink 2. We then searched for other
proteins previously not known to be as signaling-related
ones, but having interaction with a component already
included. For this, we used the same PPI resources as
for the TF-network. Based on the algorithms of the Ref.
[19], we predicted directions for the PPIs.
Figure 1 The multi-layered structure of SignaLink 2. Layers are from different sources and contain different types of interactions. The image
of an onion is used to illustrate this structure. The core of the database contains the interactions between pathway member proteins. In the first
layer these proteins are connected with pathway regulators, such as scaffold and endocytotic proteins. The next two layers contain the first
neighbor interactors of these proteins. The interactors have a predicted enzymatic effect (second layer) or a known physical interaction (third
layer) to the members of the core or the first layer. The fourth and the fifth layers contain the transcription factors (TFs) and miRNA regulators of
the already listed proteins, respectively. The fifth layer also contains the TFs of these miRNAs.
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post-transcriptional regulatory networks that control
the expression of signaling components and their
interactors. TF–TF binding site interactions were used
to list transcriptional connections between TFs and
genes encoding signaling components or pathway
interactors. We downloaded experimental and pre-
dicted data from the EdgeDB, REDFly, DroID, ABS,
JASPAR, HTRIdb, OregAnno, ENCODE and PAZAR
databases [15,20-27]. We also included two types of
miRNA network data: i) miRNA–mRNA interactions
from miRBase, TarBase, Miranda, TargetScan and
miRecords [28-32], and ii) TFs of these miRNAs from
PutMir, TransMir and ENCODE [27,33,34]. For each
regulatory interaction, binding scores were calculatedbased on position matrix values or inserted from the
original sources.
Integrating the sources and quality control
The core of SignaLink 2 contains the interactions of
pathway member proteins and their regulators (endo-
cytotic and scaffold proteins). This data is derived from
manual curation of the literature, and has been entered
into the database directly. All the other layers of the
database were acquired from external resources. To inte-
grate these resources with the core of SignaLink 2 and
with each other, we used the original accession numbers
of the imported databases (i.e., Entrez Gene ID, NCBI
Gene ID, Gene symbols, Ensembl ID, WormBase ID,
FlyBase ID, etc.) and mapped them to UniProt Primary
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gration process and the structure of SignaLink 2 are
shown in Figure 2. The final number of proteins and
interactions in each layer is listed in Table 1.
For every data source containing integrated data sets
that is interactions collected with different methods,
quality control is highly important. For each PPI, we cal-
culated a confidence score based on a GO semantic
similarity score [36] (Figure 3a). By performing a ROC
curve analysis, we determined two cut-off scores to get
three confidence categories. We set the lower cut-off
score to 0.2 to divide low- and medium-confidence PPIs.
At this cut-off score the false negative rate (FN/N) was
0.058 (i.e. 5.8% of the PPIs were false negatives), and the
true positive rate (TP/P) was 0.42 (i.e., 42% of the ex-
perimentally known PPIs were true positives). A second
cut-off score was also calculated to distinguish between
medium and high-confidence PPIs. This cut-off was set
to 0.6 with 0.8 true positive rate and 0.23 false negative
rate. Applying these cut-off scores we found that, for ex-
ample for humans, SignaLink 2 contains 16,343 low-
confidence PPIs (35.2%), 26,214 medium-confidenceFigure 2 The construction and structure of SignaLink 2. First, with man
pathway proteins and included information on scaffold and endocytotic pr
proteins in the manually curated core of SignaLink 2. With this step we also
pathway regulator proteins. Then, we integrated the transcription factors (T
their interactions with the mRNAs of all the already inserted proteins. We aPPIs (56.5%) and 3,837 (8.3%) high-confidence PPIs
(Figure 3a). Thus, nearly the two-third of the PPIs in
SignaLink 2 has medium or high-confidence scores.
Note the high number of high-confidence PPIs, which
possibly resulted from the common signaling-related
functions of the interacting proteins. For PPIs in
humans, we also evaluated the interactions with the
PRINCESS PPI-evaluation tool [37] (Figure 3b). Calcula-
tion of the PRINCESS score involves multiple data types,
thus, it can be calculated only for a limited set of inter-
acting proteins for which these information is available.
Consequently, we could calculate PRINCESS scores for
2,266 PPIs. Using 2.0 as the default cut-off score of
PRINCESS [37], we found 1,067 low-confidence PPIs
(47.1%) and 1,199 high-confidence PPIs (52.9%)
(Figure 3b). Most of the high-confidence PPIs were ori-
ginally found by the manual curation of SignaLink 2. We
note that PRINCESS score highly depends on the quality
of the available information on the interacting proteins.
Thus, upon more information will be available, the num-
ber of PPIs above the cut-off may increase. We also note
that users can optionally decide to set other cut-offual curation we updated previous pathway data, extended the set of
oteins. Then, we integrated the protein-protein interactions affecting
imported first neighbor proteins of the pathway member and
F) that regulate all these proteins. Finally, we integrated miRNAs and
lso added the TFs of the imported miRNAs.
Table 1 Detailed statistics of SignaLink 2
Species C. elegans D. melanogaster H. sapiens
Layers Nodes Edges Nodes Edges Nodes Edges
Pathway members 198 253 210 260 1,150 1,640
Pathway regulators 0 0 0 0 751 2,122
Post-translational modifiers 916 3,072 1,713 6,896 4,682 82,852
Directed protein-protein interactors 49 47 128 171 951 3,252
Undirected protein-protein interactors 100 245 166 496 1,387 6,086
TF regulators 152 187 998 16,319 2,585 30,736
miRNA regulators 806 9,658 939 5,308 2,844 245,857
TFs of miRNAs 25 19 0 0 716 5,209
SignaLink 2 contains different amounts of proteins/miRNAs in each layer in each species, according to the data from the literature and external sources. See the
main text for details on the layers and sources. For C. elegans and D. melanogaster, no data was available for pathway regulator scaffold proteins and for TFs that
regulate miRNAs.
Fazekas et al. BMC Systems Biology 2013, 7:7 Page 5 of 15
http://www.biomedcentral.com/1752-0509/7/7scores or simply download the PPIs without a cut-off fil-
ter. We note that we could calculate confidence scores
for an average of 58% interactions (74,152 PPI in the
three species, from which 61,380 PPIs were found in
humans). For the remaining interactions the GO annota-
tions of the interacting protein pairs were not known.
Thus, SignaLink 2 could contain false positive interac-
tions. Applying confidence scores, checking the litera-
ture references listed in SignaLink or using other
evaluation tools could help the users to filter the most
probable interactions for their analysis. In the case of
other binding interactions (e.g., TF-TFBS or mRNA-
miRNA), we used the original scores of the source. Dis-
tinction of predicted and experimentally verifiedFigure 3 Confidence scores for human protein-protein interactions (P
similarity score [36]. We determined cut-off scores at 0.2 and 0.6 to divide l
detailed information was available for the interacting proteins, we also calc
[37]. By default, PRINCESS sets it cut-off score at 2.0. More than the half (52interactions is also important. Thus, we grouped all the
integrated sources accordingly, and implemented an easy
selection option at the download page, where users can
decide the type of interactions (i.e., original sources) to
be included. Furthermore, all scores and details can be
customized by advanced users (for details, see the Utility
section), allowing a personalized level of quality and
confidence to be set.
We also note that all experimental interactions in Sig-
naLink either collected by manual curation or integra-
tion of other sources were coming from various cell
types and experimental conditions. Therefore, interac-
tions in SignaLink 2 are the sum of many possible inter-
actions but not all of these interactions can happen atPIs). a) Confidence scores calculated based on a GO semantic
ow-, medium- and high-confidence PPIs. b) For PPIs in humans where
ulated another confidence score with the PRINCESS PPI-evaluation tool
.9%) of the evaluated PPIs were above this value.
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localization and tissue expression data to the networks
of SignaLink 2 to filter compartment- or tissue-specific
interactions, respectively. We plan to include such data
types in the next version of SignaLink.
Database structure
SignaLink 2 stores data in a MySQL database (for the
database schema, see Figure 4), where each record in the
protein or miRNA tables represents one real protein or
miRNA, respectively, and one real entity is represented
only by one record. Proteins might belong to pathways
(stored in the protein_pathway table) and have topo-
logical attributes (stored in the protein_topology table)
such as ligand, receptor, mediator, co-factor, transcrip-
tion factor, scaffold, endocytosis-related. Within layers,
each interaction has one or more sources. For eachFigure 4 The SQL database scheme of SignaLink 2. The core of the dat
one protein and one miRNA. Each record in the protein or mirna tables rep
only by one record. There can be more than one interaction between two
sources (what databases are they originated from) and reference annotatio
Interaction_source table connects interaction and source tables, while inter
interaction has the attributes whether it is direct or indirect (interaction.is_d
inhibitory (interaction.is_stimulation) stored in the interaction table. The inte
binding and confidence scores are stores. Other supplementary tables coninteraction we list the original database(s) from which it
was integrated into SignaLink 2. These database sources
are listed in the source table, where each source has an
attribute whether the source contains experimentally
verified or predicted interactions. In addition, each inter-
action has one or more literature references (i.e., original
publication(s) about the interaction, retrieved from the
integrated databases). References are listed in the refer-
ence table. In the interaction table, each interaction also
has attributes whether it is direct or indirect, directed or
undirected, stimulatory or inhibitory. For example, direct
interaction occurs between a kinase and its phosphoryl-
ation target; and we mean indirect interaction between a
transcription factor and its target gene, or between two
proteins that are members of a complex but no evi-
dence is known that they directly bind to each other.
All literature-curated interactions in SignaLink 2 areabase is the interaction table. Interactions can be between proteins or
resents one real protein or miRNA, and one real entity represented
nodes, but only one within each layer. Within layers, interactions have
ns (what publications do contain information about them)
action_reference table connects interaction and reference tables. Each
irect), directed or undirected (interaction.is_directed), stimulatory or
raction table is connected to the score_interaction table, in which
tain names and IDs of proteins. See the main text for details.
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from external resources, we predicted a single direction.
Thus, these interactions are also listed as directed, while
the remaining PPIs for which we could not determine
the direction are listed as undirected. Interactions may
have stimulatory or inhibitory effect. Where we could
not determine the effect from the original publication
or sources, we mention "stimulatory or inhibitory
interaction". An interaction may have multiple scores,
which are stored at the interaction_score table. This
table contains the original scores from ELM Structure
Filter, TarBase, miRecords, miRanda, PicTar, TargetScan,
PutMir and JASPAR as well as the confidence scores we
generated with a GO Semantic Similarity-based method
and with the PRINCESS protein interaction evaluation
tool [36,37].
Utility
User-friendly web interface
The webpage processes data with PHP on the server
side, and jQuery on the client side, providing a great
user experience in all standard compliant browsers. To
display interactive networks, we use the Cytoscape Web
plugin [38]. The search method performs partial match
on multiple types of names and database IDs, finding
the proteins and miRNAs matching the text typed in by
the user. The search field helps the user in autocomplet-
ing the text while typing.
The protein datasheets of the website display all infor-
mation stored in SignaLink 2 about the queried protein.
In Figure 5, the protein datasheet of AXIN1 is shown.
(AXIN1 was used as an example to illustrate the usage of
the website, described in detail in the Discussion section.)
On the top of a protein datasheet basic information is
shown: name, species-specific database (Wormbase, Fly-
base, ENSEMBL) IDs and UniProt accessions. All of
these IDs are hyperlinked to the corresponding website
to help discovering further details. In the case of pathway
member proteins, basic information also includes path-
way memberships and topological properties. On the
protein datasheet, users can interactively explore the
interactions of the queried protein both with a list, where
interactions are grouped by layers, and with an inter-
active network visualization of these interactions. In both
cases, the user can easily obtain information on each
interaction, including the type of the interaction (direct/
indirect, directed/undirected, stimulatory/inhibitory, pre-
dicted/experimentally verified), interaction scores from
the original source (if applicable) and confidence scores
generated by SigaLink 2. The evidence for the interaction
is shown with PubMed links to the external source from
where we integrated the given interaction, and PubMed
links to the original paper used as a reference. The infor-
mation originated from different integrated resources iseasily comparable, and bi-directional relations also have
good visibility. The URLs of the protein datasheets are
constructed simply from the proteins’ UniProt IDs,
with a scheme similar to that of UniProt, e.g., http://
signalink.org/protein/P00533. In addition, all protein
datasheets can be accessed with gene names or
species-specific database IDs allowing the easy link-
ing of these datasheets from other webpages or
resources (e.g., http://signalink.org/protein/sma-3, http://
signalink.org/protein/FBgn0004859). We have included a
comprehensive FAQ site and inserted short popup help-
boxes in most of the web pages to support the users.
Download options
The entire database is available as a MySQL dump file. Al-
ternatively, we developed a BioMART-like customizable
download page, where users can easily select and combine
the species, pathways, layers and the file format of down-
load. The customized subnetworks can be downloaded in
various formats: CSV, BioPAX, SBML, PSI-MI tab or PSI-
MI XML and in a Cytoscape CYS file. Data can be com-
pressed by GNU zip or zip. After selecting the details of
the download, for advanced users, we offer additional
customization where within each layer the different source
databases can be filtered by score values, or even excluded.
A general switch is also available to exclude all predicted
interactions.
All user-specified download options are automatically
transformed to MySQL queries. For each download, we
generate a URL, where users can access the data for 14
days. Optionally, users can provide their e-mail addresses
to which files smaller than 10 MB will be e-mailed. We
have developed a download module (written in Python),
to manage the queries and to convert the result of the
queries to user-specified file formats. In conclusion,
SignaLink 2 serves as an integrated signaling re-
source where the origin, type and confidence level of
each interaction are clearly listed, allowing the user
to easily access and filter data.
Discussion
Applications of SignaLink 2
Signaling cross-talks are important connections be-
tween different pathways and can generate novel in-
put–output combinations as well as maintain the
dynamic adaptation of the signaling system [39,40].
We have previously shown the significance of multi-
pathway proteins (i.e., proteins functioning in more
than one pathway) in the intertwined network of sig-
naling pathways [1]. However, to ensure that an appro-
priate response is transduced, multi-pathway proteins
need to be precisely regulated. SignaLink 2 contains
multiple forms of protein regulation, including tran-
scriptional, post-transcriptional and post-translational
Figure 5 Functionality of the protein datasheet at the SignaLink.org website. a) This box contains basic information about the protein,
AXIN1: references to other databases, topological features and pathway memberships. b) The protein datasheet lists all interactions of AXIN1,
grouped by layers. Expanding one layer, users are able to browse the list of interactions. c) In this view the properties of the interactions
(direction, direct or indirect, stimulatory or inhibitory) are visible. More details (database sources of the interaction, literature references and
scores) can be accessed by one click. d) An interactive network of first neighbors is available, visualized by the CytoscapeWeb plugin [38].
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each cross-talking protein can be analyzed.
Though cross-talk is generally defined as a physical inter-
action between pathway proteins, genetic studies often
point out the importance of pathway cross-talks through
transcription. In this case, cross-talk is mediated by a ter-
minal transcription factor (TF) of a given pathway that reg-
ulates the expression of a component of another pathway
[41,42]. With SignaLink 2, transcription-mediated pathway
connections can be mapped as it contains i) uniformly
defined pathways, ii) TFs for each pathway, and iii) a TF-
regulatory network. Transcription-mediated cross-talks
can be identified between any two pathways or globally at
the systems-level. Recently, miRNAs have also been shown
as important regulators of signaling pathways and net-
works [43,44]. As some miRNAs are known or predicted
to be regulated by specific TFs [33,34], pathway cross-talks
can be formed by a terminal TF of a pathway that regu-
lates the expression of a miRNA down-regulating a com-
ponent of another pathway. As an integrated database,
SignaLink 2 contains TF and miRNA regulation data as
well as a uniformly curated pathway dataset. These prop-
erties allow researchers to analyze pathway cross-talks on
the post-transcriptional level. Furthermore, systems-level
comparison of transcriptional, post-transcriptional and
post-translational (i.e., PPI mediated) cross-talks can be
performed with SignaLink 2.
Modeling signaling networks is a key approach to
understand their dynamic properties in adaptation and
diseases [45,46]. However, most PPI resources contain
most interactions without direction (an information that
is critical in signal transduction), pathway databases are
often curated without uniform curation protocol and
pathway definition, and generally lack important compo-
nents having no direct signaling functions (i.e., scaffolds
proteins, ubiquitin ligases and many phosphatases). As
function of these components is the spatial and temporal
regulation of the signaling flow, including them to a
pathway resource could facilitate more precise modeling
of signaling systems. As SignaLink 2 contains these com-
ponents, it can enhance the development of models that
can be successfully validated in wet lab experiments.
Furthermore, data in SignaLink 2 is ready to use for
modeling programs and scripts as users can download
the files in well-known network and modeling formats
(e.g., SMBL, BioPAX). User-specific selection of Signa-
Link 2 can be integrated with experimental data on en-
zyme activity or binding strength, thus, SignaLink 2
provides a general network topology for in-depth differ-
ential equitation modeling. Data from SignaLink 2 can
be easily integrated to Boolean modeling frameworks,
such as CellNetOptimizer [47]. Combining SignaLink 2
dataset (i.e., signaling pathways and regulatory compo-
nents) with network data of other cellular processes,such as autophagy or apoptosis, would allow Bayesian
modeling on the regulation of these processes.
Genome programs and high-throughput screenings
have greatly contributed to the construction of signaling
networks in various model organisms, ranging from
invertebrates to mammals. Reliable network resources
enable the prediction of novel components and func-
tions by analyzing cross-species data with the toolbox of
functional genomics [48,49]. Accordingly, for C. elegans,
D. melanogaster and H. sapiens, we have predicted 271
novel signaling components (i.e., signalogs) based on
ortholog information of the previous version of Signa-
Link [50]. SignaLink 2 contains updated and extended
dataset allowing the identification of further signalogs.
In addition, SignaLink 2 enables the prediction of regu-
logs (i.e., predicted regulatory connections) as it contains
TFs and regulatory connections for three metazoan spe-
cies in a unified data structure [51].
Studying cross-talks, pathway regulator TFs and miRNAs
have high pathological relevance as their malfunction
often lead to diseases such as cancer [52]. Earlier, we
found a significant change in the expression level of
multi-pathway proteins in hepatocellular carcinoma [1],
indicating that integration of signaling networks with ex-
pression datasets could reveal novel diagnostic and prog-
nostic markers. The multilevel regulatory networks of
SignaLink 2 have higher coverage and could serve as a
more precise resource to compare normal and disease
states of signaling networks.
Pharmacological targeting of key signaling compo-
nents, including multi-pathway proteins and miRNAs is
a promising strategy [53-55]. But unfortunately, numer-
ous failures are known where the drug target had undis-
covered or underestimated cross-talk as well as
regulatory effects [56,57]. With SignaLink 2 different
layers of signaling pathway regulation can be examined
within a single resource. Performing an in silico perturb-
ation analysis on the multi-layered signaling network of
SignaLink 2 may facilitate the development of pharma-
cological interventions [54,58,59]. A perturbation ana-
lysis with SignaLink 2 can uncover key proteins or
interactions important in the robustness of the signaling
network. We have recently reviewed several such net-
work perturbation approaches [60]. SignaLink 2 allows
drug developers to measure the regulatory influence of a
drug target candidate as well as to predict the signal-
ing effect of its targeting. For example, drug targeting
of a TF or its upstream interactor may influence the
expression of many target genes, including signaling-
related feedback mechanisms or metabolic enzymes
important in drug metabolism. Applying the multi-
layered network of SignaLink 2 could help developers
to identify and avoid such circuits. SignaLink 2 can
also support the identification of multiple targets in a
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the primarily suggested drug targets in the network of
SignaLink 2 would allow the short listing of a minimal
set of key targets with maximal impact on the net-
work. Similarly, in anti-cancer strategy often not a sin-
gle biochemical species is targeted but a complete
pathway [60]. The stimulatory and inhibitory cross-
talks and regulatory circuits of SignaLink 2 allow the
listing of key regulators of a pathway, whose modula-
tion can have pathway-level effects.
Examples
First, we illustrate the usage of the SignaLink.org website
with a protein, AXIN1. Next, the advantages of the
download options of SignaLink 2 are illustrated with an
integrated map of Notch and TGF-β pathways.
We selected AXIN1 to demonstrate how regulatory
interactions can be examined for a given protein with
the protein datasheet of the SignaLink 2 website. With
the previous version of SignaLink, we found that AXIN1
is a multi-pathway protein having connection to more
than one pathway [1]. Accordingly, AXIN1 was also
described as a master scaffold for multiple signaling
pathways [20]. Besides its distinct roles in the WNT,
TGF-β and MAPK pathways, AXIN also has cross-talk
functions [20]. Thus, one can think that AXIN1 should
be precisely regulated. Here, we intended to explore how
AXIN1 can be regulated to act as a multi-pathway pro-
tein and a master scaffold for members of different path-
way. If we search for ‘AXIN1’ on the SignaLink 2
website, we will get its protein datasheet. On the top of
the datasheet basic information about AXIN1 are pre-
sented (Figure 5a): 1) hyperlinks to AXIN1's page in
other databases (Ensembl and UniProt); 2) AXIN1 is
listed in SignaLink 2 as a mediator and a scaffold pro-
tein, and had been assigned to three pathways: RTK,
WNT/Wingless and TGF. Below this box, the list of
AXIN1 interactions can be found, grouped by layers
(Figure 5b). In some cases the list is rather long, so each
layer is expanded only if the user clicks on the layer’s
title, and an optional sliding box on the left side of the
page helps in navigation. In this view the names of inter-
acting protein pairs, the type of interactions (coded with
arrows) and pathway memberships are also visible. We
can see that SignaLink 2 contains: 1) 15 interactions be-
tween AXIN and different pathway member proteins;
2) 8 interactions where AXIN as a scaffold regulates
pathway proteins; 3) 136 predicted post-translational
modifications (i.e., enzymes that may modify AXIN1);
4) 9 known PPIs predicted to be directed; 5) 17 pre-
dicted or known transcription factors that regulate
AXIN1; 6) 28 predicted or known miRNAs that
could down-regulate AXIN1; 7) Finally, 30 PPIs with-
out any direction. Note that interactions can overlapbetween the layers, but these overlaps are mentioned for
each relevant interaction. In certain cases, some overlaps
can point out important feedbacks, showing a protein that
interacts with and regulates AXIN1. Users can search or
browse for each interactor/regulator of AXIN at the top of
the list of layers. If we expand the first layer (Figure 5b), we
can see that the first two interactions are direct stimulatory
(normal arrow), the third one is indirect and inhibitory
(dashed line with blunted arrow). To get more information
about an interaction (for example, about the interaction
between AXIN1 and PPP2CA), a simple click on the list is
enough. Then, in the same box detailed information is
shown (expanded in Figure 5c): the interaction between
AXIN1 and PPP2CA was manually curated, two references
to articles hyperlinked to PubMed can also be seen. In the
list of sources, beside SignaLink, two integrated databases,
BioGrid and HPRD, are also listed as having data about this
interaction. At the bottom of this box, a GO semantic simi-
larity score with a value of 0.53 is shown as a predicted
level of confidence. The details of this score can be
examined with a hyperlink to its original article. On the
right side of the protein datasheet page, an interactive
image of the network of first neighbors of AXIN1 takes
place (Figure 5d). By default, in this network we can see
that AXIN1 has 17 first neighbors among pathway
members and scaffold-partners. Many of these neigh-
bors are connected also to each other, e.g. APC2 and
GSK3B, which form a feed-forward loop with AXIN1.
Layers are color-coded, while interaction types are
signed by arrow shapes. Different layers can be
shown or hidden, and the network image can be
switched to full screen mode easily with a control
panel that also serves as a figure legend. To facilitate
further exploration of the AXIN1 network, any click
on the nodes of the network image will direct the
user to the datasheet any protein or miRNA. In con-
clusion, the integrated regulatory data shown for
AXIN1 in the SignaLink 2 website lists and points
out molecular components, which are capable to
regulate the expression or the function of AXIN1. As
malfunction of AXIN1 is implicated in many dis-
eases, including for example colon cancer [61], iden-
tification of AXIN1 regulators could serve as novel
therapeutic targets. A short list of suggested – alternative –
targets that could modulate AXIN1 could be important as
currently there is no drug against AXIN1 (according to
DrugBank and PharmGKB [62,63]). This strategy is in
agreement with the recently proposed allo-network drug
concept, whose effects can propagate across several pro-
teins, to enhance or inhibit specific interactions along a
pathway [64]. However, further experimental tests and
global screens should clarify the tissue- and context-
specific roles of these AXIN1 regulators, as well as their
possible pharmacological applicability. We believe that
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such promising components.
To illustrate the usage of SignaLink 2 download
options, we selected two pathways, Notch and TGF-β.
These two pathways have mostly different biochemical
reactions and their members have distant evolutionary
relations. Both pathways have been extensively studied
as cross-talking pathways, having connections with other
pathways [65,66]. Interestingly, in many cases Notch and
TGF-β pathways have different functions, but in special
cases they do cross-talk [67,68]. For a systems-level
identification of these cross-talks, we need an integrated
map of the Notch and TGF-β pathways. With SignaLink
2, this map can be generated, downloaded and visualized
easily with Cytoscape [69]. On the Download page of
SignaLink 2, we have selected both Notch and TGF-β
pathways, their pathway regulators (scaffolds and endo-
cytotic proteins), as well as their transcriptional and
post-transcriptional regulators (i.e., TFs and miRNAs, re-
spectively). (We have not included other layers to focus
on these three groups.) We have chosen the Cytoscape
format, which allowed us to start working with the net-
work right after we have downloaded it. Note that the
SQL query behind this download is quite complex, thus,
generation of the Cytoscape file needs time. When we
opened the Cytoscape file, we used the attributes already
implemented for the nodes and edges of the network.
Thus, no further data imports were necessary. We
grouped the components to Notch, TGF-β and mutual
groups, and for the sake of visibility and simplicity, we
excluded those components that belonged to other path-
ways. Components of other pathways were originally
included in the file as they had cross-talks with Notch
and/or TGF-β pathway components. Then, using the fil-
tering and network layout options of Cytoscape, we have
created three images showing the protein-protein, tran-
scriptional and post-transcriptional regulatory interac-
tions of the two pathways. On Figure 6a, we can see the
members and the interactions of Notch and TGF-β
pathway proteins (blue nodes and edges), their scaffold
and endocytotic proteins (green nodes and edges). Tran-
scription factors of the pathways are highlighted with or-
ange. This image shows that the pathways have 13
cross-talking proteins that bridge the pathways. Both
pathways have specific and also mutual scaffolds and tar-
get TF. Note that these TFs are not regulators but the
terminal components of the pathways. All the protein
numbers are shown in parentheses. On Figure 6b, the
transcriptional regulation of the two pathways is visua-
lized. For the sake of clarity, we only visualized experi-
mentally verified transcriptional interactions. This
filtering can be done either before downloading the file
using the Advanced Filter option of SignaLink 2, or after
the download by using the Filter option of Cytoscape asall interactions can be filtered by their source. In this
network image, TFs that regulate the expression of the
pathway members and the scaffold/endocytotic compo-
nents are listed and grouped by their pathway specificity.
The high number of mutual TFs indicates a regulated co-
expression of Notch and TGF-β pathway members. This
is in agreement with the earlier finding that Notch and
TGF-β pathways have a high-level of cross-talks [67,68]
(i.e., co-expression of cross-talking proteins is essential
to form cross-talks). Interestingly, some of the terminal
TFs, already listed in Figure 6a, regulate miRNAs and
not proteins. These TFs have a light blue border and
they have a cyan colored edge to their target miRNAs
(shown with light blue nodes). These miRNAs are
regulated by the pathways. Note that in our analysis
we found miRNAs that are regulated by both pathways
and not specifically by one of the pathways. These 80
mutual miRNAs can be interpreted as another example
for the high-level cooperation between the Notch and
TGF-β pathways. However, it is important to note that
we have data on the miRNA regulation role for only a
subset of TFs. Thus, upon new TF-miRNA regulatory
interactions will be described, we may be able to iden-
tify miRNAs regulated by only one pathway. On
Figure 6c, we show the post-transcriptional regulations
of the already listed proteins. The miRNAs that could
down-regulate a protein are shown with dark red hav-
ing red colored interactions. For visibility reasons, we
have excluded the high number of predicted interac-
tions retrieved from TargetScan. We found 5 miRNAs
that specifically target TGF-β pathway components.
Compared to the mutual 180 miRNAs, these miRNAs
could serve as specific regulators of the TGF-β path-
ways, while not affecting the Notch pathway. The
merged network image in Figure 6d presents the inte-
grated map of Notch and TGF-β pathways. For the
mutual miRNAs we could identify two distinct sets:
We found 80 miRNAs regulated by both pathways that
are capable to regulate members of both pathways,
while 100 miRNAs can regulate members of both
pathways but they are regulated by other pathways.
The 80 miRNAs can be considered as mediators of
post-transcriptional cross-talks between Notch and
TGF-β pathways. Consequently, miRNAs regulated by
other pathways, but targeting TGF-β or TGF-β and
Notch pathway members could be the possible media-
tors of further pathway cross-talks on the post-
transcriptional level. Recently, the role of miRNA in
the regulation of Notch, TGF-β and other pathways
has been highlighted in hepatocellular carcinoma and
cancer stem cells [70]. We believe that SignaLink 2
could serve as a systems-level resource to list
pathway-specific and mutual miRNAs as well as cross-
talks on the post-transcriptional level. This list may
Figure 6 Visualization of the multi-level cross-talk between Notch and TGF-β pathways to illustrate the capabilities of a SignaLink 2
download file. In each part of the figure, text boxes show the color legend of the nodes. Number of components is listed in parentheses. a)
Protein-protein interactions of Notch and TGF-β pathway members, transcription factors, scaffold and endocytotic proteins. Interactions between
pathway members and of transcription factors (TFs) are shown with blue edges, while the interaction of scaffold and endocytotic proteins are
shown with green edges. b) Transcriptional regulations of Notch and TGF-β pathway members, TFs, scaffold/endocytotic proteins and miRNAs.
Transcriptional regulations of proteins and miRNAs are shown with orange and light blue edges, respectively. Those TFs that regulate miRNAs are
highlighted with a light blue border. c) Post-transcriptional regulations of Notch and TGF-β pathway members, TFs and scaffold/endocytotic
proteins. Post-transcriptional connection between miRNAs and their target proteins is shown with red edges. d) An integrated Notch – TGF-β
map. This is a merged network image of the previous three networks. With textboxes we highlighted cross-talk regulating miRNAs. See the main
text for the details of each network. The networks were analyzed and visualized with Cytoscape [69].
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the role of these miRNAs in pathway functions. In
conclusion, using SignaLink 2 data with Cytoscape, we
could generate and visualize a multi-level cross-talk
network of the Notch and TGF-β pathways, identify
mutual and pathway-specific components/regulators, as
well as point out important TFs and miRNAs that
could regulate cross-talk between these two pathways
and other pathways. We note that many of these interac-
tions may be highly context-specific and experimentalvalidation is needed to confirm the function of each
inter-pathway connection.
Comparison with other resources
Several excellent resources already exist that contain
similar information as SignaLink 2. In Table 2 we
compare the major features of SignaLink 2 with three
well-known pathway databases, with two integrated
resources and with the first version of SignaLink. We
note that one of the resources, ConsensusPathDB,
Table 2 Comparison of resources with SignaLink 2
KEGG
[71]
Reactome
[72]
SPIKE
[73]
ConsensusPathDB
[74]
TranscriptomeBrowser
[10]
SignaLink 1
[1]
SignaLink
2
Model species# √ √ √
Containsmanual curation§ √ √ √ √ √
Contains integrated data √ √ √
Reference for each interaction √ √ √ √
Cross-talks and multi-pathway proteins* √ √ √
Undirected protein-protein interactions √ √ √ √ √
Directed protein-protein interactions† √ √
Transcription factor regulation √ √ √ √
miRNA regulation √ √
Transcription factors that regulate miRNAs √
Confidence score for the interactions √
Customizable download options √ˣ √ √
Freely downloadable for academic users √ √ √ √ √ √
We compared the major features of SignaLink 2 with three pathway databases (KEGG, Reactome and SPIKE), an integrated pathway resource, ConsensusPathDB, and an
integrated regulatory resource, TranscriptomeBrowser. We also compared the features of SignaLink 2 with its previous version to show the major upgrade and extension.
#Only those species were taken into account that were represented with experimental data in the resource (i.e., orthology derived predictions were not considered). § Manual
curation performed by the developers of the resource (i.e., not integrated from external resources). * All types of cross-talks (transcriptional, post-transcriptional and post-
translational) were taken into account but only in those cases where the structure of the resource allowed to easily download cross-talks and multi-pathway proteins (i.e.,
without any computational evaluation). † Only protein-protein interactions (PPIs) with predicted directions were taken into account. ˣ Only available with the
InteractomeBrowser plugin.
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resources contain valuable data but none of them have
all the features and data types as SignaLink 2 does.
Furthermore, as compared to other signaling resources,
SignaLink 2 has the following unique features: 1) it
contains experimental data not only from humans but
for two invertebrate model organisms; 2) combines
large-scale datasets with manual curation; 3) provides
confidence scores for each interaction; 4) operates a
highly customizable download page with multiple file
formats. Most resources contain different data types in
one database, making their selection difficult. Accord-
ing to our comparison, SignaLink 2 was the only re-
source that lists the transcriptional, post-transcriptional
and post-translational regulators of a pathway. In Signa-
Link 2, these data types are stored in a multi-layered
structure allowing users a simple way to analyze the
layers of interest in the signaling network. We acknow-
ledge that SignaLink 2 contains data for seven pathways,
while some resources (e.g., KEGG, Reactome) contain
significantly more pathways. As pathways in SignaLink 2
encompass major developmental and important disease-
related pathways, we believe that the overall information
it can provide fills a gap and supports a more detailed
analysis of these pathways.
We previously compared the number of proteins and
interactions between SignaLink 1, KEGG, Reactome and
NetPath [1]. Since this comparison only the datasets of
SignaLink and Reactome has improved significantly,
thus, here we present an updated comparison betweenSignaLink 2 and Reactome. We compared the proteins
and interactions of five pathways (JAK/STAT, Notch,
RTK, TGF-β and WNT) present in both SignaLink 2
and Reactome. We found that 331 proteins and 848
interactions were present in both resources. 677 proteins
and 5,962 interactions were SignaLink-specific, while
916 proteins and 5,365 interactions were Reactome-spe-
cific. Previously we also compared the curation strategies
of SignaLink and Reactome and suggested the high num-
ber of protein complex based interactions in Reactome
and the significant bias towards specific enzyme func-
tions (e.g., proteolysis) as a possible explanation of the
high number resource-specific proteins and interactions
[1]. Overall, we think that SignaLink 2 both complements
the datasets found in other databases, such as Reactome
and supports a more detailed analysis of these pathways
by including transcriptional, post-transcriptional and
possible post-translational regulators of a pathway.
Future plans
Knowing that the list of components and interactions in
each layer is not complete, we will include further ex-
perimentally validated datasets yearly, which will com-
plement the manual curation update we perform every
two years. We also intend to include cellular compart-
ment and tissue-specific localization information to fu-
ture versions of SignaLink. In addition, we will increase
the number of integrated hyperlinks in the protein data-
sheet page and develop connections to medical and
drug-related resources.
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We presented the upgraded and extended version of the
SignaLink resource that allows users to explore signaling
pathway interactions and to identify pathway regulators,
as well as transcriptional and post-transcriptional regula-
tory components. With SignaLink 2 users can examine in
a single resource how scaffolds, enzymes, TFs or miRNAs
regulate cross-talks and signaling flow. We hope that
SignaLink 2 will be an efficient resource for modeling
signaling systems as well as for signaling-related net-
work medicine and pharmacology.
Availability and requirements
Non-profit users can access SignaLink 2 free of charge
at http://SignaLink.org.
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